Sayfa yüklenirken bir hata oluştu.
Teknik ekibimiz bilgilendirildi, ancak sorunun devam etmesi durumunda lütfen e-posta destek widget ile bize ulaşın.
| Metrics | Range | Conclusion |
|---|---|---|
| Selected LTM EBIT Multiple | -34,2x - -37,8x | -36,0x |
| Selected Fwd EBIT Multiple | 11,4x - 12,6x | 12,0x |
| Fair Value | $2,60 - $2,88 | $2,74 |
| Upside | -55,4% - -50,6% | -53,0% |
| Benchmarks | Ticker | Full Ticker |
| CANbridge Pharmaceuticals Inc. | 1228 | SEHK:1228 |
| Keymed Biosciences Inc. | 2162 | SEHK:2162 |
| Jiangsu Aidea Pharmaceutical Co., Ltd. | 688488 | SHSE:688488 |
| Abbisko Cayman Limited | 2256 | SEHK:2256 |
| InnoCare Pharma Limited | 9969 | SEHK:9969 |
| Ascentage Pharma Group International | ASPH.F | OTCPK:ASPH.F |
| - | - | - |
| Select LTM EBIT Multiple | |||||||
| Benchmark Companies | |||||||
| 1228 | 2162 | 688488 | 2256 | 9969 | ASPH.F | ||
| SEHK:1228 | SEHK:2162 | SHSE:688488 | SEHK:2256 | SEHK:9969 | OTCPK:ASPH.F | ||
| Historical EBIT Growth | |||||||
| 5Y CAGR | NM- | NM- | NM- | NM- | NM- | NM- | |
| 3Y CAGR | NM- | NM- | NM- | NM- | NM- | NM- | |
| Latest Twelve Months | 7.1% | -36.9% | 18.4% | 95.8% | 44.4% | 57.5% | |
| Historical EBIT Profit Margin | |||||||
| 5 Year Average Margin | -1026.6% | -317.1% | -27.4% | -1922.1% | -5547.7% | -1913.9% | |
| Prior Fiscal Year | -356.3% | -129.2% | -25.8% | -2681.4% | -90.9% | -401.8% | |
| Latest Fiscal Year | -400.1% | -146.2% | -36.3% | -4.3% | -54.0% | -38.6% | |
| Latest Twelve Months | -400.1% | -146.2% | -19.4% | -4.3% | -32.9% | -38.6% | |
| Current Trading Multiples | |||||||
| EV / LTM Revenue | 3.02x | 25.09x | 11.88x | 7.80x | 16.41x | 27.46x | |
| EV / LTM EBITDA | -0.8x | -19.5x | -118.4x | -364.5x | -60.2x | -90.1x | |
| EV / LTM EBIT | -0.8x | -17.2x | -61.3x | -182.2x | -49.9x | -71.1x | |
| Low | Mid | High | |||||
| Benchmark EV / LTM EBIT | -182.2x | -49.9x | -0.8x | ||||
| Historical EV / LTM EBIT | -71.1x | -8.3x | -6.0x | ||||
| Selected EV / LTM EBIT | -34.2x | -36.0x | -37.8x | ||||
| (x) LTM EBIT | (379) | (379) | (379) | ||||
| (=) Implied Enterprise Value | 12,956 | 13,638 | 14,320 | ||||
| (-) Non-shareholder Claims * | (378) | (378) | (378) | ||||
| (=) Equity Value | 12,578 | 13,260 | 13,942 | ||||
| (/) Shares Outstanding | 676.1 | 676.1 | 676.1 | ||||
| Implied Value Range | 18.60 | 19.61 | 20.62 | ||||
| FX Rate: CNY/USD | 7.2 | 7.2 | 7.2 | Market Price | |||
| Implied Value Range (Trading Cur) | 2.60 | 2.74 | 2.88 | 5.83 | |||
| Upside / (Downside) | -55.4% | -53.0% | -50.6% | ||||
| Equity Waterfall | |||||||
| Benchmark Companies | |||||||
| (in millions) | 1228 | 2162 | 688488 | 2256 | 9969 | ASPH.F | |
| Enterprise Value | 259 | 10,703 | 6,208 | 3,876 | 20,387 | 28,595 | |
| (+) Cash & Short Term Investments | 11 | 2,156 | 453 | 2,008 | 7,008 | 1,267 | |
| (+) Investments & Other | 0 | 210 | 1 | 0 | 0 | 34 | |
| (-) Debt | (136) | (753) | (482) | (24) | (1,545) | (1,668) | |
| (-) Other Liabilities | 0 | (1) | (96) | 0 | (17) | (10) | |
| (-) Preferred Stock | 0 | 0 | 0 | 0 | 0 | 0 | |
| (-) Other | 0 | 0 | 0 | 0 | 0 | 0 | |
| Value of Common Equity | 134 | 12,315 | 6,085 | 5,860 | 25,833 | 28,217 | |
| (/) Shares Outstanding | 424.6 | 294.6 | 420.8 | 625.8 | 2,063.0 | 676.1 | |
| Implied Stock Price | 0.31 | 41.80 | 14.46 | 9.36 | 12.52 | 41.73 | |
| FX Conversion Rate to Trading Currency | 0.91 | 0.91 | 1.00 | 0.91 | 0.91 | 7.16 | |
| Implied Stock Price (Trading Cur) | 0.35 | 45.80 | 14.46 | 10.26 | 13.72 | 5.83 | |
| Trading Currency | HKD | HKD | CNY | HKD | HKD | USD | |
| FX Rate to Reporting Currency | 0.91 | 0.91 | 1.00 | 0.91 | 0.91 | 7.16 | |